Sign In
Buy ZBH
$93.93
-1.03 (-1.08%)
At Close: Jul 31, 2026
Zimmer (ZBH) Reports Q3 Earnings: What Key Metrics Have to Say
10:35am, Wednesday, 30'th Oct 2024
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Stree
Implant maker Zimmer Biomet lowers full-year profit forecast
09:22am, Wednesday, 30'th Oct 2024
Hip implant maker Zimmer Biomet lowered its annual profit forecast on Wednesday following last month's disruptions to a software platform that was managing some of the company's operations.
Zimmer Biomet (ZBH) Misses Q3 Earnings Estimates
08:41am, Wednesday, 30'th Oct 2024
Zimmer Biomet (ZBH) came out with quarterly earnings of $1.74 per share, missing the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.65 per share a year ago.
What to Expect From These 3 MedTech Stocks This Earnings Season
12:31pm, Tuesday, 29'th Oct 2024
Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow.
Countdown to Zimmer (ZBH) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
10:21am, Tuesday, 29'th Oct 2024
Evaluate the expected performance of Zimmer (ZBH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
Zimmer Biomet to Debut New Z1™ Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting
07:30am, Monday, 28'th Oct 2024
Company's Booth Spotlights Comprehensive Hip Portfolio and Enabling Technologies Including OrthoGrid Hip AI® and HAMMR™ Automated Hip Impaction System WARSAW, Ind. , Oct. 28, 2024 /PRNewswire/ -- Z
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
11:08am, Wednesday, 23'rd Oct 2024
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
11:16am, Wednesday, 16'th Oct 2024
Zimmer Biomet's third-quarter results are likely to reflect the strength in its three business segments, namely Hips, Knees and S.ET.
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2024 Financial Results
07:30am, Wednesday, 09'th Oct 2024
WARSAW, Ind. , Oct. 9, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, October 30, 2024 a
Dublin, Oct. 07, 2024 (GLOBE NEWSWIRE) -- The "Large Joint Devices Market Size, Share, and Trends Analysis Global 2024-2030 MedSuite Includes: Knee Replacement Market, Hip Replacement Market, and 1 mo
Zimmer Biomet: The Undervalued Titan Of Joint Replacements
03:58pm, Wednesday, 02'nd Oct 2024
Zimmer Biomet, a leader in musculoskeletal health, excels in knee and hip replacements, and surgical robots, making it a sticky choice for many orthopedic surgeons. Competitive advantages include stro
Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?
12:37pm, Friday, 06'th Sep 2024
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
Zimmer Biomet Stock Falls After the Medtech Firm Warns of Software Switch Impact
03:52pm, Thursday, 05'th Sep 2024
Shares of Zimmer Biomet Holdings (ZBH) dropped nearly 9% after the manufacturer of artificial joint replacements and other orthopedic products warned the implementation of a new enterprise resources p
Zimmer Biomet Names David DeMartino as Senior Vice President, Investor Relations
07:30am, Thursday, 05'th Sep 2024
WARSAW, Ind. , Sept. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that David DeMartino will join the Company as Senior
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
09:00am, Wednesday, 04'th Sep 2024
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
